Bloomberg has reported that Boston Scientific has abandoned its plans to auction off its neuromodulation business, which it had hoped to sell for up to $2 billion. Sources say companies interested in a deal were looking to pay $1 billion to $1.5 billion for the pain treatment division--much less that Boston Sci was asking. Article